Skip to Content
Merck
  • Antimalarial target vulnerability of the putative Plasmodium falciparum methionine synthase.

Antimalarial target vulnerability of the putative Plasmodium falciparum methionine synthase.

PeerJ (2024-01-19)
Nirut Leela, Parichat Prommana, Sumalee Kamchonwongpaisan, Tana Taechalertpaisarn, Philip J Shaw
ABSTRACT

Plasmodium falciparum possesses a cobalamin-dependent methionine synthase (MS). MS is putatively encoded by the PF3D7_1233700 gene, which is orthologous and syntenic in Plasmodium. However, its vulnerability as an antimalarial target has not been assessed. We edited the PF3D7_1233700 and PF3D7_0417200 (dihydrofolate reductase-thymidylate synthase, DHFR-TS) genes and obtained transgenic P. falciparum parasites expressing epitope-tagged target proteins under the control of the glmS ribozyme. Conditional loss-of-function mutants were obtained by treating transgenic parasites with glucosamine. DHFR-TS, but not MS mutants showed a significant proliferation defect over 96 h, suggesting that P. falciparum MS is not a vulnerable antimalarial target.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-HA-Tag antibody, Rabbit Monoclonal, recombinant, expressed in HEK 293 cells, clone RM305, purified immunoglobulin
Pricing and availability is not currently available.